You are here: Home » 2023 » March » Archives for 22nd

UNFI EQUITY ALERT: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages United Natural Foods, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – UNFI

NEW YORK, March 22, 2023 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of United Natural Foods, Inc. (NYSE: UNFI) between March 10, 2021 and March 7, 2023, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 19, 2023.

SO WHAT: If you purchased United Natural Foods securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the United Natural Foods class action, go to https://rosenlegal.com/submit–form/?case_id=13471 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 19, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) that, despite its cost saving Value Path initiative, United Natural Foods had not invested in improving its data management and related infrastructure; (2) that, as a result, the Company could not respond adequately to cost changes, such as inflationary pressure; (3) that, as a result, the Company could not appreciate the benefits of procurement gains and inventory gains achieved during fiscal 2022; (4) that, as a result of the foregoing, the Company's profitability would be materially adversely impacted; and (5) and that as a result of the foregoing, Defendant's positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the United Natural Foods class action, go to https://rosenlegal.com/submit–form/?case_id=13471 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8793630)

Nyxoah Reports Fourth Quarter and Full Year 2022 Financial and Operating Results

REGULATED INFORMATION

Nyxoah Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
Completed all 115 implants in the DREAM U.S. pivotal study

Mont–Saint–Guibert, Belgium "" March 22, 2023 09:05pm CET / 4:05pm ET "" Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the fourth quarter and full year 2022.

Recent Financial and Operating Highlights

  • Completed all 115 implants in the DREAM U.S. pivotal trial, with 12–month data expected early next year.
  • Filed the first module in the modular PMA submission.
  • Submitted 12–month data1 on the first 34 DREAM patients as a late–breaking abstract to SLEEP 2023 demonstrating a 65% AHI responder rate, a 76% ODI responder rate and safety in–line with expectations. These data are preliminary and not conclusive of final DREAM success.
  • Achieved quarterly sales of 1.3 million resulting in a sequential German market share gain.
  • Ended the year with 38 active German accounts, up from 12 entering 2022.
  • Strengthened supply chain with Belgium manufacturing facility receiving clearance from the EU notified body.
  • Implanted the first patients in the ACCCESS U.S. IDE pivotal study to treat complete concentric collapse (CCC). Implant completion expected in 2024.
  • Total cash position of 94.8 million at the end of 2022.

2023 Key Objectives

  • Focus on patient follow up in the DREAM study resulting in reaching the primary endpoints.
  • U.S. regulatory, manufacturing and market access readiness.
  • Drive further revenue and market share growth in Germany.

"With all 115 implants completed in the DREAM study and our first PMA module submitted, we achieved key milestones towards U.S. FDA approval. Our attention now focuses on patient follow up. With the clearance of our second manufacturing site, we have strengthened our supply chain to meet increasing demand," commented Olivier Taelman, Nyxoah Chief Executive Officer.

Mr. Taelman continued, "Commercially in Europe, we are excited to see the continued demand growth for Genio in Germany. Our growing experience with CCC patients in Europe, driven by our expanded label, reinforces our confidence in our ongoing U.S. ACCCESS study."

Fourth Quarter and Full Year 2022 Results

UNAUDITED CONDENSED CONSOLIDATED FINANCIAL INFORMATION "" CONSOLIDATED STATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS FOR THE THREE MONTHS AND YEARS ENDED DECEMBER 31, 2022 AND DECEMBER 31, 2021 (in thousands)

For the three months ended December 31, For the year ended December 31,
2022 2021 2022 2021
Revenue 1,307 295 3,084 852
Cost of goods sold (465) (105) (1,150) (303)
Gross profit 842 190 1,934 549
Research and Development Expense (4,575) (3,335) (15,861) (12,344)
Selling, General and Administrative Expense (5,363) (3,937) (18,855) (14,712)
Other income/(expense) 46 539 283 265
Operating loss for the period (9,050) (6,543) (32,499) (26,242)
Financial income (4,609) 3,603 6,763 3,675
Financial expense 1,153 (588) (4,320) (2,072)
Loss for the period before taxes (12,506) (3,528) (30,056) (24,639)
Income taxes (790) (2,720) (1,169) (2,980)
Loss for the period (13,296) (6,248) (31,225) (27,619)
Loss attributable to equity holders (13,296) (6,248) (31,225) (27,619)
Other comprehensive income/(loss)
Items that may not be subsequently reclassified to profit or loss (net of tax)
Remeasurements of post–employment benefit obligations, net of tax 70 (68) 70 (68)
Items that may be subsequently reclassified to profit or loss (net of tax)
Currency translation differences (82) (17) (96) 121
Total other comprehensive income/(loss) (12) (85) (26) 53
Total comprehensive loss for the year, net of tax (13,308) (6,333) (31,251) (27,566)
Loss attributable to equity holders (13,308) (6,333) (31,251) (27,566)
Basic loss per share (in EUR) (514) (238) (1,209) (1,161)
Diluted loss per share (in EUR) (514) (238) (1,209) (1,161)

UNAUDITED CONDENSED CONSOLIDATED FINANCIAL INFORMATION "" CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS OF DECEMBER 31, 2022 AND
DECEMBER 31, 2021 (in thousands)

As of December 31,
2022 2021
ASSETS
Non–current assets
Property, plant and equipment 2,460 2,020
Intangible assets 39,972 25,322
Right of use assets 3,159 3,218
Deferred tax asset 47 46
Other long–term receivables 173 164
45,811 30,770
Current assets
Inventory 882 346
Trade receivables 1,463 226
Other receivables 1,775 2,286
Other current assets 1,284 1,693
Financial assets 76,968 '
Cash and cash equivalents 17,888 135,509
100,260 140,060
Total assets 146,071 170,830
EQUITY AND LIABILITIES
Capital and reserves
Capital 4,440 4,427
Share premium 228,275 228,033
Share based payment reserve 5,645 3,127
Other comprehensive income 176 202
Retained loss (118,212) (87,167)
Total equity attributable to shareholders 120,324 148,622
LIABILITIES
Non–current liabilities
Financial debt 8,189 7,802
Lease liability 2,586 2,737
Pension liability ' 80
Provisions 59 12
Deferred tax liability ' 5
10,834 10,636
Current liabilities
Financial debt 388 554
Lease liability 719 582
Trade payables 4,985 3,995
Current tax liability 3,654 2,808
Other payables 5,167 3,633
14,913 11,572
Total liabilities 25,747 22,208
Total equity and liabilities 146,071 170,830

Revenue

Revenue was 1.3 million for the fourth quarter ending December 31, 2022, compared to 295,000 for the fourth quarter ending December 31, 2021. Revenue for the full year of 2022 was 3.1 million, compared to 0.9 million for the full year of 2021. The increase in revenue was attributable to the Company's commercialization of the Genio system, primarily in Germany.

Cost of Goods Sold

Cost of goods sold was 465,000 for the three months ending December 31, 2022, representing a gross profit of 0.8 million, or gross margin of 64.4%. This compares to total cost of goods sold of 105,000 in the fourth quarter of 2021, for a gross profit of 190,000, or gross margin of 64.4%.

For the full year ending December 31, 2022, total cost of goods sold was 1.2 million, representing a gross profit of 1 million, or gross margin of 62.7%. This compares to total cost of goods sold of 303,000 for the full year of 2021, for a gross profit of 0.5 million or gross margin of 64.4%.

Research and Development Expenses

Research and development expenses were 4.6 million for the three months ending December 31, 2022, versus 3.3 million for the prior year period, reflecting the Company's investments in the development of next generation versions of the Genio system as well as ongoing clinical studies, most notably DREAM in the U.S.

For the full year ending December 31, 2022, research and development expenses were 15.9 million, versus 12.3 million for the full year of 2021.

Selling, General and Administrative Expenses

Selling, general and administrative expenses rose to 5.4 million for the fourth quarter of 2022, up from 3.9 million in the fourth quarter of 2021. This was due primarily to increased commercial efforts in Germany and other European markets, as well as investments in Nyxoah's corporate infrastructure. The Company expects to continue adding headcount across the organization ahead of the U.S. commercial launch.

For the full year ending December 31, 2022, selling, general and administrative expenses were 18.9 million, up from 14.7 million for the full year 2021 due to increased commercial efforts in Germany and investments in Nyxoah's corporate infrastructure.

Operating Loss

Total operating loss for the fourth quarter and full year 2022 was 9.1 million and 32.5 million, respectively, versus 6.5 million and 26.2 million in the fourth quarter and full year 2021, respectively. This was driven by the acceleration in the Company's R&D spending, as well as ongoing commercial and clinical activities.

Cash Position
As of December 31, 2022, cash and financial assets totaled 95 million, compared to 135.5 million on December 31, 2021. Total cash burn was approximately 3.4 million per month during 2022.

Full year report 2022
Nyxoah's financial report for the full year of 2022, including details of the audited consolidated results, are available on the investor page of Nyxoah's website (https://investors.nyxoah.com/financials).

Conference call and webcast presentation
Nyxoah will conduct a conference call open to the public today at 10:30pm CET / 4:30pm ET, which will also be webcast. To participate in the conference call, please access the following link to register for a dial–in number: https://register.vevent.com/register/BI84592a0d5f1d4395a204ebca89873f13

A question–and–answer session will follow the presentation of the results. To access the live webcast, go to https://investors.nyxoah.com/events. The archived webcast will be available for replay shortly after the close of the call.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah's lead solution is the Genio system, a patient–centered, leadless and battery–free hypoglossal neurostimulation therapy for OSA, the world's most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors' therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution "" CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward–looking statements
Certain statements, beliefs and opinions in this press release are forward–looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations regarding the Genio system; planned and ongoing clinical studies of the Genio system; the potential advantages of the Genio system; Nyxoah's goals with respect to the development, regulatory pathway and potential use of the Genio system; the utility of clinical data in potentially obtaining FDA approval of the Genio system; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward–looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward–looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20–F for the year ended December 31, 2021, filed with the Securities and Exchange Commission ("SEC") on March 24, 2022, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward–looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward–looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward–looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward–looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward–looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward–looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward–looking statements, which speak only as of the date of this press release.

Contacts:
Nyxoah
David DeMartino, Chief Strategy Officer
david.demartino@nyxoah.com
+1 310 310 1313

1 For the trial to be successful, of the 115 patients, at least 63% of patients need to be AHI and ODI responders at the 12–month follow–up.

Attachment


GLOBENEWSWIRE (Distribution ID 1000799654)

Nyxoah Annonce ses Résultats Financiers et Opérationnels pour le Quatrième Trimestre et l'Année 2022

INFORMATIONS RGLEMENTES

Nyxoah Annonce ses Rsultats Financiers et Oprationnels pour le Quatrime Trimestre et l'Anne 2022
Achvement des 115 implants de l'tude pivot amricaine DREAM

Mont–Saint–Guibert, Belgique "" 22 mars 2023, 21h05 CET / 16h05 ET "" Nyxoah SA (Euronext Bruxelles/Nasdaq : NYXH) ( Nyxoah ou la Socit ) opre dans le secteur des technologies mdicales et se concentre sur le dveloppement et la commercialisation de solutions innovantes destines traiter le Syndrome d'Apnes Obstructives du Sommeil (SAOS). La Socit a publi aujourd'hui ses rsultats financiers et oprationnels pour le quatrime trimestre et l'anne 2022.

Faits Marquants Financiers et Oprationnels Rcents

  • Achvement des 115 implants de l'essai pivot DREAM aux tats–Unis, les donnes 12 mois tant attendues au dbut de l'anne prochaine.
  • Dpt du premier module de la demande d'autorisation de mise sur le march (PMA) modulaire.
  • Prsentation des donnes 12 mois1 sur les 34 premiers patients DREAM en tant que late–breaking abstract SLEEP 2023, dmontrant un taux de rponse l'IAH de 65 %, un taux de rponse l'ODI de 76 % et une scurit conforme aux attentes. Ces donnes sont prliminaires et ne permettent pas de conclure au succs final de DREAM.
  • Les ventes trimestrielles ont atteint 1,3 million d'euros, ce qui s'est traduit par un gain squentiel de parts de march en Allemagne.
  • Fin de l'anne avec 38 comptes allemands actifs, contre 12 au dbut de l'anne 2022.
  • Renforcement de la chane d'approvisionnement avec l'obtention de l'autorisation de l'organisme notifi de l'UE pour l'usine de fabrication en Belgique.
  • Implantation des premiers patients de l'tude pivot amricaine ACCCESS IDE pour le traitement de l'affaissement concentrique complet (CCC). L'achvement de l'implantation est prvu pour 2024.
  • Trsorerie totale de 94,9 millions d'euros la fin de 2022.

Objectifs Cls en 2023

  • Se concentrer sur le suivi des patients dans l'tude DREAM afin d'atteindre les objectifs principaux.
  • Prparation la rglementation, la fabrication et l'accs au march aux tats–Unis.
  • Poursuivre la croissance du chiffre d'affaires et de la part de march en Allemagne.

"Avec l'achvement des 115 implants de l'tude DREAM et la soumission de notre premier module PMA, nous avons franchi des tapes cls vers l'approbation par la FDA amricaine. Notre attention se porte dsormais sur le suivi des patients. Avec l'autorisation de notre deuxime site de fabrication, nous avons renforc notre chane d'approvisionnement pour rpondre la demande croissante”, a comment Olivier Taelman, CEO de Nyxoah.

M. Taelman a poursuivi : “Sur le plan commercial en Europe, nous sommes ravis de constater la croissance continue de la demande de Genio en Allemagne. Notre exprience croissante avec les patients atteints de CCC en Europe, grce notre indication thrapeutique largie, renforce notre confiance dans l'tude ACCCESS en cours aux tats–Unis.”

Rsultats du Quatrime Trimestre et de l'Anne 2022

INFORMATIONS FINANCIRES CONSOLIDES NON AUDITES – TATS CONSOLIDS DES PERTES ET DES AUTRES PERTES COMPRHENSIBLES POUR LES TROIS MOIS ET LES EXERCICES CLOS LE 31 DCEMBRE 2022 ET LE 31 DCEMBRE 2021 (en milliers)

Pour le trimestre clos le 31 dcembre Pour l'exercice termin le 31 dcembre
2022 2021 2022 2021
Chiffre d'affaires 1.307 295 3.084 852
Cot des biens vendus –465 –105 –1.150 –303
Bnfice brut 842 190 1.934 549
Frais de recherche et de dveloppement –4.575 –3.335 –15.861 –12.344
Frais de vente, dpenses administratives et autres frais gnraux –5.363 –3.937 –18.855 –14.712
Autres revenus / (frais) d'exploitation 46 539 283 265
Perte d'exploitation de la priode –9.050 –6.543 –32.499 –26.242
Produits financiers –4.609 3.603 6.763 3.675
Charges financires 1.153 –588 –4.320 –2.072
Perte de la priode avant impts –12.506 –3.528 –30.056 –24.639
Impts sur le revenu –790 –2.720 –1.169 –2.980
Perte de la priode –13.296 –6.248 –31.225 –27.619
Perte attribuable aux actionnaires –13.296 –6.248 –31.225 –27.619
Autres lments du rsultat global
Elments pouvant tre reclassifis en bnfices ou en pertes (nets d'impts)
Revaluation des obligations des avantages posterieurs a l emploi 70 –68 70 –68
Differences de change –82 –17 –96 121
Total des autres lments du rsultat global –12 –85 –26 53
Perte globale totale de la priode, nette d'impts –13.308 –6.333 –31.251 –27.566
Perte attribuable aux actionnaires –13.308 –6.333 –31.251 –27.566
Perte par action (en ) –514 –238 –1.209 –1.161
Perte dilue par action (en ) –514 –238 –1.209 –1.161

INFORMATIONS FINANCIRES CONSOLIDES CONDENSES NON AUDITES – TAT CONSOLID DE LA SITUATION FINANCIRE AU 31 DCEMBRE 2022 ET AU 31 DCEMBRE 2021 (EN MILLIERS)

Au 31 dcembre
2022 2021
ACTIFS
Actifs non courants
Immobilisations corporelles 2.460 2.020
Immobilisations incorporelles 39.972 25.322
Droit d'utilisation d'actifs 3.159 3.218
Actif d'impts diffrs 47 46
Autres crances long terme 173 164
45.811 30.770
Actifs courants
Stocks 882 346
Crances commerciales 1.463 226
Autres crances 1.775 2.286
Autres actifs courants 1.284 1.693
Actifs financiers 76.968 '
Trsorerie et quivalents de trsorerie 17.888 135.509
100.260 140.060
Total de l'actif 146.071 170.830
CAPITAUX PROPRES ET PASSIFS
Capital et rserves
Capital 4.440 4.427
Prime d'mission 228.275 228.033
Rserve pour paiement fonds sur des actions 5.645 3.127
Autres lments du rsultat global 176 202
Rsultats reports (118,212) (87,167)
Total des capitaux propres attribuables aux actionnaires 120.324 148.622
PASSIFS
Passifs non courants
Dettes financires 8.189 7.802
Passifs locatifs 2.586 2.737
Passifs au titre des retraites ' 80
Provisions 59 12
Passif d'impts diffrs ' 5
10.834 10.636
Passifs courants
Dettes financires 388 554
Passifs locatifs 719 582
Dettes commerciales 4.985 3.995
Passif d'impts exigibles 3.654 2.808
Autres dettes 5.167 3.633
14.913 11.572
Total du passif 25.747 22.208
Total des capitaux propres et du passif 146.071 170.830

Chiffre d'affaires

Le chiffre d'affaires s'est lev 1,3 million d'euros pour le quatrime trimestre clos le 31 dcembre 2022, contre 295 000 euros pour le quatrime trimestre clos le 31 dcembre 2021. Le chiffre d'affaires pour l'ensemble de l'anne 2022 s'est lev 3,1 millions d'euros, contre 0,9 million d'euros pour l'ensemble de l'anne 2021. L'augmentation du chiffre d'affaires est attribuable la commercialisation par la Socit du systme Genio , principalement en Allemagne.

Cot des produits vendus

Le cot des marchandises vendues tait de 465 000 pour les trois mois se terminant le 31 dcembre 2022, soit une marge brute de 0,8 million d'euros, ou une marge brute de 64,4 %. titre de comparaison, le cot total des marchandises vendues tait de 105 000 au quatrime trimestre 2021, pour un bnfice brut de 190 000 , soit une marge brute de 64,4 %.

Pour l'ensemble de l'exercice clos le 31 dcembre 2022, le cot total des marchandises vendues s'est lev 1,2 million d'euros, soit un bnfice brut de 1,9 million d'euros, ou une marge brute de 62,7 %. titre de comparaison, le cot total des marchandises vendues tait de 303 000 pour l'ensemble de l'anne 2021, soit un bnfice brut de 0,5 million d'euros ou une marge brute de 64,4 %.

Frais de recherche et dveloppement

Les frais de recherche et dveloppement se sont levs 4,6 millions d'euros pour le trimestre clos le 31 dcembre 2022, contre 3,3 millions d'euros pour l'exercice prcdent, refltant les investissements de la Socit dans le dveloppement des versions de nouvelle gnration du systme Genio ainsi que les tudes cliniques en cours, plus particulirement DREAM aux tats–Unis.
Pour l'ensemble de l'exercice clos le 31 dcembre 2022, les frais de recherche et dveloppement se sont levs 15,9 millions d'euros, contre 12,3 millions d'euros pour l'ensemble de l'exercice 2021.

Frais commerciaux, gnraux et administratifs

Les frais commerciaux, gnraux et administratifs ont augment 5,4 millions d'euros au quatrime trimestre 2022, contre 3,9 millions d'euros au quatrime trimestre 2021. Cela s'explique principalement par l'intensification des efforts commerciaux en Allemagne et sur d'autres marchs europens, ainsi que par des investissements dans l'infrastructure de l'entreprise Nyxoah. La socit prvoit de continuer ajouter des effectifs dans l'ensemble de l'organisation avant le lancement commercial aux tats–Unis.
Pour l'exercice complet se terminant le 31 dcembre 2022, les frais de vente, gnraux et administratifs se sont levs 18,9 millions d'euros, contre 14,7 millions d'euros pour l'exercice complet 2021, en raison de l'intensification des efforts commerciaux en Allemagne et des investissements dans l'infrastructure d'entreprise de Nyxoah.

Perte d'exploitation

La perte d'exploitation totale pour le quatrime trimestre et l'exercice 2022 s'est leve 9,1 millions d'euros et 32,5 millions d'euros, respectivement, contre 6,5 millions d'euros et 26,2 millions d'euros pour le quatrime trimestre et l'exercice 2021, respectivement. Cette volution s'explique par l'acclration des dpenses de R&D de la Socit, ainsi que par les activits commerciales et cliniques en cours.

Situation de trsorerie
Au 31 dcembre 2022, la trsorerie et les actifs financiers s'levaient 94,9 millions d'euros, contre 135,5 millions d'euros au 31 dcembre 2021. La consommation totale de trsorerie a t d'environ 3,4 millions d'euros par mois au cours de l'anne 2022.

Rapport annuel 2022
Le rapport financier de Nyxoah pour l'ensemble de l'anne 2022, y compris les dtails des rsultats consolids vrifis, sont disponibles sur la page des investisseurs du site Web de Nyxoah (https://investors.nyxoah.com/financials).

Confrence tlphonique et prsentation par webcast
Nyxoah tiendra une confrence tlphonique ouverte au public aujourd'hui 22h30 CET / 16h30 ET, qui sera galement diffuse sur le web. Pour participer la confrence tlphonique, veuillez accder au lien suivant afin de vous inscrire pour obtenir un numro d'appel : https://register.vevent.com/register/BI84592a0d5f1d4395a204ebca89873f13

Une sance de questions–rponses suivra la prsentation des rsultats. Pour accder la webdiffusion en direct, rendez–vous l'adresse suivante : https://investors.nyxoah.com/events. Le webcast archiv pourra tre rcout peu aprs la clture de l'appel.

propos de Nyxoah
Nyxoah opre dans le secteur des technologies mdicales. Elle se concentre sur le dveloppement et la commercialisation de solutions innovantes destines traiter le Syndrome d'Apnes Obstructives du Sommeil (SAOS). La principale solution de Nyxoah est le systme Genio , une thrapie de neurostimulation du nerf hypoglosse sans sonde et sans batterie qui a reu le marquage CE, centre sur le patient et destine traiter le Syndrome d'Apnes Obstructives du Sommeil (SAOS), le trouble respiratoire du sommeil le plus courant au monde. Ce dernier est associ un risque accru de mortalit et des comorbidits, dont les maladies cardiovasculaires. La visions de Nyxoah est que les patients souffrant de SAOS doivent pouvoir profiter de nuits rparatrices et vivre pleinement leur vie.

la suite de la finalisation probante de l'tude BLAST OSA, le systme Genio a reu le marquage europen CE en 2019. Nyxoah a ralis avec succs deux IPO : l'une sur Euronext Bruxelles en septembre 2020 et l'autre sur le NASDAQ en juillet 2021. Grce aux rsultats positifs de l'tude BETTER SLEEP, Nyxoah a reu le marquage CE pour l'extension de ses indications thrapeutiques aux patients souffrant de collapsus concentrique complet (CCC), pour lesquels les thrapies concurrentes sont actuellement contre–indiques. En outre, la Socit mne actuellement l'tude pivot IDE DREAM pour la FDA obtenir l'autorisation de mise sur le march.

Pour de plus amples informations, veuillez consulter le site http://www.nyxoah.com/.

Attention "" marquage CE depuis 2019. Dispositif de recherche aux tats–Unis. Limit un usage exprimental aux tats–Unis par la loi fdrale amricaine.

Dclarations prospectives
Le prsent communiqu de presse comprend certaines dclarations, croyances et opinions prospectives, qui refltent les attentes actuelles de la Socit ou de ses directeurs (le cas chant) concernant le systme Genio ; les tudes cliniques planifies et en cours sur le systme Genio ; les avantages potentiels du systme Genio ; les objectifs de Nyxoah en ce qui concerne le dveloppement, le mcanisme rglementaire et l'utilisation potentielle du systme Genio ; l'utilit des donnes cliniques dans l'obtention ventuelle de l'approbation du systme Genio par la FDA et les rsultats de la Socit, ses finances, ses liquidits, ses performances, ses perspectives, sa croissance et ses stratgies. Par leur nature, les dclarations prospectives impliquent un certain nombre de risques, d'incertitudes, de suppositions et d'autres facteurs pouvant entraner des rsultats ou des vnements qui diffrent de manire significative de ceux exprims ou impliqus par les dclarations prospectives. Ces risques, incertitudes, suppositions et facteurs peuvent avoir un effet ngatif sur le rsultat et les effets financiers des plans et des vnements dcrits dans la prsente. Plusieurs facteurs, dont entre autres une volution de la demande, de la concurrence et de la technologie, peuvent engendrer une diffrence notable entre l'volution anticipe et les vnements, les rsultats ou les performances rels. Les dclarations prospectives de ce communiqu de presse concernant des tendances ou des activits passes ne sont pas des garanties de performances futures et ne doivent pas tre comprises comme assurant la poursuite de ces tendances ou de ces activits l'avenir. En outre, mme si les rsultats ou les volutions rels correspondent aux dclarations prospectives contenues dans ce communiqu de presse, ces rsultats ou volutions peuvent ne pas tre reprsentatifs des rsultats ou des dveloppements futurs. Aucune reprsentation ni garantie n'est faite quant l'exactitude ou la justesse des dclarations prospectives. En consquence, la Socit dcline expressment toute obligation de publication de mises jour ou de rvisions des dclarations prospectives de ce communiqu de presse en lien avec toute volution des attentes ou des vnements, conditions, suppositions ou circonstances sur lesquels ces dclarations prospectives se basent, sauf en cas d'obligation lgale. Ni la Socit ni ses conseillers, ses reprsentants, ses filiales ou leurs reprsentants et employs ne garantissent l'exactitude des suppositions sur lesquelles se basent les dclarations prospectives ni n'acceptent la responsabilit de l'exactitude future des dclarations prospectives comprises dans ce communiqu de presse ou de la survenue des volutions anticipes. Il est conseill de ne pas vous fier indment ces dclarations prospectives, qui ne sont valides qu' la date de la publication de ce communiqu de presse.

Contacts:
Nyxoah
David DeMartino, Chief Strategy Officer
david.demartino@nyxoah.com
+1 310 310 1313

1 Pour que l'essai soit concluant, il faut qu'au moins 63 % des 115 patients rpondent l'IAH et l'ODI lors du suivi 12 mois.

Pice jointe


GLOBENEWSWIRE (Distribution ID 1000799654)

Destilaria Glen Grant Lança Novo Whisky Escocês Single Malt de 21 Anos Celebrando uma Explosão de Sabor Tropical

ROTHES, Escócia, March 22, 2023 (GLOBE NEWSWIRE) — A Destilaria Glen Grant, localizada no corao de Speyside, anunciou o importante lanamento do seu novo whisky single malt de 21 anos. Sendo a expresso mais antiga da coleo permanente e disponvel a partir de maro de 2023, o whisky de 21 anos sinaliza o incio de uma nova era de explorao para a destilaria de 180 anos.

Impulsionada por uma viso singular h mais de 180 anos, a destilaria The Glen Grant se baseia em uma busca constante para criar os single malts mais singulares, aromticos e evocativos. Inspirados pelo legado de James Grant, "O Major" "" o visionrio excntrico mais influente que colocou a marca no seu caminho inovador "" unimos a inspirao de todo o mundo na criao de whiskies excepcionais e fascinantes que celebram o esprito da inovao. Esta inspirao global o que separa o The Glen Grant de muitos dos seus vizinhos de Speyside, sendo o nosso norte em um caminho nico que vem definindo o nosso seu legado duradouro desde 1840.

Quando viajava para locais distantes, o Major trazia uma coleo ecltica de frutas e plantas para Rothes que eram exibidas em estufas vitorianas desenhadas pessoalmente por ele e, mais tarde, em um jardim de 27 acres no corao da destilaria.

A criao do The Glen Grant 21 Anos representa um momento definitivo na evoluo do The Glen Grant e marca um novo captulo da sua histria. Abrindo o portflio de expresses de prestgio do The Glen Grant, este whisky de 21 anos se junta famlia de whiskies single malt de 10, 12, 15 e 18 anos e d o tom para uma srie de inovaes a serem lanadas a partir de 2023.

Para o Master Distiller Dennis Malcolm OBE, isso tambm marca uma conquista orgulhosa na sua carreira de mais de 60 anos. Ao selecionar manualmente a combinao perfeita dos barris de pontas de xerez oloroso, barricas e ex–Bourbon do Armazm Nmero 4, o mais antigo armazm de pedra tradicional da destilaria, Dennis uniu a sua essncia para criar os sabores cativantes que do vida a um intenso carter frutado.

Dennis Malcolm, Master Distiller, disse: "Este whisky de 21 anos marca um momento altamente significativo para The Glen Grant e ir abrir o caminho para uma nova era. Este um acontecimento empolgante que tenho certeza de que ir nos levar para o futuro com orgulho e paixo. Cada um dos nossos whiskies conta a sua prpria histria e revela a sua prpria jornada de sabores definida por um personagem cativante, com camadas que se desdobram e uma complexidade surpreendente. Estou orgulhoso e emocionado de poder compartilhar este whisky maravilhoso com o mundo e de poder dar continuidade ao nosso compromisso com a consistente qualidade que eu acredito que realmente nos diferencia."

Engarrafado a 46%, de cor natural e non–chill filtered (no filtrado a frio), este whisky de 21 anos casado em pequenos lotes para preservar a integridade dos sabores refinados e garantir sua qualidade absoluta. Tudo isso realizado na destilaria em Rothes, reforando o etos requintadamente singular do The Glen Grant.

O produto final tem um toque tropical, comeando com aroma de pssego doce maduro, caramelo e passas, e resultando em uma exploso forte de frutas tropicais, como coco, e um sabor de notas cremosas de manteiga. Um toque suave e saboroso alude a um final duradouro de crme brle caramelizado.

O Glen Grant de 21 anos est disponvel a partir de maro de 2023 nos principais mercados globais, incluindo EUA, Reino Unido e sia, com o preo sugerido de US$ 360,00.

Para mais informao
Contacte–nos em theglengrant@mcsaatchi.com
Siga–nos no Instagram @theglengrantscotch

Foto deste comunicado disponvel em https://www.globenewswire.com/NewsRoom/AttachmentNg/d51931e3–3337–4646–ac5c–fc1844c8122a

A foto tambm est disponvel na Newscom, www.newscom.com, e via AP PhotoExpress.


GLOBENEWSWIRE (Distribution ID 8793680)

La distillerie The Glen Grant dévoile un nouveau whisky single malt de 21 ans d'âge faisant la part belle à une explosion tropicale de saveurs

ROTHES, Écosse, 22 mars 2023 (GLOBE NEWSWIRE) — La distillerie The Glen Grant, situe au c"ur du Speyside, a annonc le lancement mmorable de son nouveau whisky single malt de 21 ans d'ge. Dsormais le tmoignage le plus ancien de la collection permanente, disponible compter de mars 2023, ce whisky de 21 ans d'ge marque le dbut d'une nouvelle re d'exploration pour cette distillerie prsente depuis 180 ans.

Porte depuis plus de 180 ans par une ambition unique, la distillerie The Glen Grant met profit une recherche constante visant crer les single malts les plus uniques, aromatiques et vocateurs. Inspirs par l'hritage du Major James Grant (la force motrice visionnaire et excentrique qui a fait prendre la marque la voie de l'ingniosit), nous rassemblons les inspirations du monde entier pour crer des whiskies exceptionnels et intrigants qui clbrent l'esprit d'innovation. Cette caractristique d'inspiration mondiale est ce qui diffrencie la distillerie The Glen Grant d'un grand nombre de ses voisins du Speyside et l'a guide le long d'un chemin bien diffrent, dfinissant ainsi son hritage prsent depuis 1840.

Aprs avoir voyag dans des contres lointaines, le Major a rassembl une collection clectique de fruits et de plantes, qu'il a ramens Rothes et prsents dans ses serres en verre victoriennes qu'il avait personnellement conues, et plus tard dans son jardin de 11 hectares situ au c"ur de la distillerie.

La cration de The Glen Grant de 21 ans d'ge reprsente un moment dcisif dans l'volution de The Glen Grant et entame un nouveau chapitre de son histoire. Se tenant aux portes des tmoignages du prestige du portefeuille The Glen Grant, ce whisky de 21 ans d'ge rejoint la famille des whiskies single malt de 10, 12, 15 et 18 ans d'ge et donne le ton un ventail de nouvelles mises en vente innovantes qui seront dvoiles partir de 2023.

Pour le matre–distillateur Dennis Malcolm, Officier dans l'ordre de l'Empire britannique, cela marque galement un aboutissement aurol de fiert dans ce rle qu'il occupe depuis plus de 60 ans. En slectionnant la main la combinaison parfaite de fts de sherry Oloroso, de Hogshead et d'anciens fts de Bourbon conservs dans l'entrept numro 4, le plus ancien entrept de fardage traditionnel en pierre de la distillerie, Dennis Malcolm a mari l'alcool afin de crer des saveurs captivantes donnant vie une intensit de caractre fruit.

Dans ses commentaires sur cette mise en vente, le matre–distillateur Dennis Malcolm a dclar : Ce whisky de 21 ans d'ge marque un moment extrmement significatif pour The Glen Grant, un moment qui ouvre la voie une nouvelle re. C'est une avance enthousiasmante qui, je le sais, nous emmnera vers l'avenir avec fiert et passion. Chacun de nos whiskies raconte sa propre histoire et rvle son propre cheminement gustatif dfini par un caractre captivant, avec des couches qui se dvoilent et une complexit surprenante. Je suis fier et ravi de pouvoir partager ce merveilleux whisky avec le monde et de poursuivre notre engagement envers une qualit constante qui, je le crois, nous distingue vraiment.

Embouteill 46 %, de couleur naturelle et non filtr froid, ce whisky de 21 ans d'ge est mari en petits lots afin de prserver l'intgrit de ses saveurs raffines et d'assurer une qualit absolue. Tout cela est ralis sur place, la distillerie base Rothes, ce qui renforce l'thos dlicieusement unique de The Glen Grant.

Il en rsulte un caractre d'une touche tropicale, commenant par des armes de pches mres sucres, de caramel et de raisins secs qui mnent une explosion de fruits tropicaux intenses, comme la noix de coco, et de notes de beurre crmeux au got. Une sensation en bouche douce et agrable renvoie une finale longue de crme brle caramlise.

Le whisky The Glen Grant de 21 ans d'ge est disponible partir de mars 2023 sur tous les principaux marchs du monde, y compris aux tats–Unis, au Royaume–Uni et en Asie au PVC de 360 $.

Pour tout complment d'information
Contactez–nous l'adresse theglengrant@mcsaatchi.com
Suivez–nous sur Instagram @theglengrantscotch

Une photo accompagnant le prsent communiqu est disponible sur https://www.globenewswire.com/NewsRoom/AttachmentNg/d51931e3–3337–4646–ac5c–fc1844c8122a

La photo est galement disponible sur Newscom, www.newscom.com et via AP PhotoExpress.


GLOBENEWSWIRE (Distribution ID 8793680)

Glen Grant Distillery stellt neuen 21 Jahre alten Single Malt Scotch Whisky mit tropischer Geschmacksexplosion vor

ROTHES, Schottland, March 22, 2023 (GLOBE NEWSWIRE) — Die Glen Grant Distillery, im Herzen der Region Speyside gelegen, hat die bedeutsame Markteinfhrung ihres neuen 21–jhrigen Single Malt Scotch Whiskys bekanntgegeben. Dieser 21 Jahre alte Whisky ist nun der lteste in der stndigen Kollektion und ab Mrz 2023 erhltlich. Er signalisiert den Beginn einer neuen, innovativen ra fr die Brennerei, die eine 180–jhrige Geschichte aufweisen kann.

Seit ber 180 Jahren verfolgt die Glen Grant Distillery eine einzigartige Vision und ist stndig bestrebt, Single Malts mit besonders einzigartigem, aromatischem und eindrucksvollem Charakter herzustellen. Angeregt vom Vermchtnis von "Major" James Grant, dem exzentrischen Visionr hinter der Marke, sammeln wir Ideen aus aller Welt fr auergewhnliche, faszinierende und ausgesprochen innovative Whiskys. Eben durch diesen global inspirierten Charakter unterscheidet sich der Glen Grant–Whisky von vielen Erzeugnissen benachbarter Brennereien in der Speyside. Seit 1840 sorgt dieser unverwechselbare Geschmack fr ein dauerhaftes Erbe.

Von seinen Reisen in ferne Lnder brachte der Major eine eklektische Mischung von Frchten und Pflanzen nach Rothes zurck und stellte sie in seinen von ihm persnlich entworfenen viktorianischen Gewchshusern und spter in einem 11 Hektar groen Garten im Herzen der Brennerei aus.

"The Glen Grant 21–Year–Old" ist ein entscheidender Moment in der Entwicklung des Glen Grant–Whiskys und ein neues Kapitel in der Geschichte des Unternehmens. Dieser 21 Jahre alte Whisky steht den prestigetrchtigen Abfllungen des Glen Grant–Portfolios bald in nichts mehr nach. Er reiht sich in die Familie der 10–, 12–, 15– und 18–jhrigen Single Malt Whiskys ein und gibt den Ton an fr eine Reihe innovativer neuer Abfllungen, die ab 2023 auf den Markt kommen werden.

Fr Master Distiller Dennis Malcolm OBE ist dies ebenfalls eine stolze Leistung in seiner mehr als 60–jhrigen Ttigkeit. Durch die handverlesene Kombination von Oloroso–Sherry–Fssern, Hogshead– und ehemaligen Bourbon–Fssern aus dem ltesten traditionellen Stein–Lagerhaus der Brennerei (Nr. 4) hat Malcolm diese Spirituose mit einem fesselnden Geschmack geschaffen, der einen intensiven, fruchtigen Charakter zum Leben erweckt.

Master Distiller Dennis Malcolm uerte sich wie folgt zu dieser Markteinfhrung: "Dieser 21 Jahre alte Whisky ist ein wichtiger Moment fr Glen Grant und der Beginn einer neuen ra. Dies ist eine aufregende Entwicklung, die uns garantiert auch knftig mit Stolz und Leidenschaft erfllen wird. Jeder unserer Whiskys erzhlt seine eigene Geschichte und offenbart seine ganz eigene Geschmacksreise, die durch ihren betrenden, mehrschichtigen, komplexen Charakter immer wieder fr berraschungen sorgt. Ich bin stolz und begeistert, dass ich diesen wunderbaren Whisky mit der Welt teilen und unser Engagement fr gleichbleibende Qualitt fortsetzen kann, die uns meiner Meinung nach wirklich auszeichnet."

Dieser 21 Jahre alte Whisky wird in kleinen Chargen hergestellt, um die Integritt der raffinierten Aromen zu bewahren und absolute Qualitt zu gewhrleisten. Er wird mit 46 % abgefllt, ist ungefrbt und wird nicht khlgefiltert. All dies geschieht vor Ort in der Brennerei in Rothes, was das einzigartige Ethos von Glen Grant unterstreicht.

Tropisch se Fruchtaromen von reifen Pfirsichen, Toffee und Rosinen fhren zu einer intensiven Geschmacksexplosion mit tropischen Frchten wie Kokosnuss und cremigen Butternoten. Das weiche, einladende Mundgefhl weicht karamellisierter Crme brle im langen Abgang.

Der "Glen Grant 21–Years–Old" ist ab Mrz 2023 in den wichtigsten Mrkten der Welt wie in den USA, dem Vereinigten Knigreich und Asien zu einer unverbindlichen Preisempfehlung von 360 $ erhltlich.

Fr weitere Informationen
Kontaktieren Sie uns untertheglengrant@mcsaatchi.com
Folgen Sie uns auf Instagram @theglengrantscotch

Ein Foto zu dieser Mitteilung ist verfgbar unter https://www.globenewswire.com/NewsRoom/AttachmentNg/d51931e3–3337–4646–ac5c–fc1844c8122a

Das Foto ist auch bei Newscom, www.newscom.com, und ber AP PhotoExpress verfgbar.


GLOBENEWSWIRE (Distribution ID 8793680)

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Tesla, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – TSLA

NEW YORK, March 22, 2023 (GLOBE NEWSWIRE) — WHY: osen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Tesla, Inc. (NASDAQ: TSLA) between February 19, 2019 and February 17, 2023, both dates inclusive (the "Class Period"), of the important April 28, 2023 lead plaintiff deadline.

SO WHAT: If you purchased Tesla securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Tesla class action, go to https://rosenlegal.com/submit–form/?case_id=12483 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 28, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) defendants had overstated the efficacy, viability, and safety of the Company's Autopilot and Full Self–Driving ("FSD") technologies; (2) Tesla's Autopilot and FSD technologies created a serious risk of accident and injury; (3) as a result of the foregoing, Tesla was subjected to an increased risk of regulatory and governmental scrutiny and enforcement action, as well as reputational harm; (4) as a result, the Company's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Tesla class action, go to https://rosenlegal.com/submit–form/?case_id=12483 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8793609)

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages SVB Financial Group Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action Commenced by the Firm – SIVB

NEW YORK, March 22, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of SVB Financial Group (NASDAQ: SIVB) between June 16, 2021 and March 10, 2023, inclusive (the "Class Period"), of the important May 12, 2023 lead plaintiff deadline in the securities class action commenced by the Firm.

SO WHAT: If you purchased SVB securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the SVB class action, go to https://rosenlegal.com/submit–form/?case_id=12882 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 12, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the Company failed to disclose to investors the risks presented by impending rising interest rates; (2) the Company failed to disclose to investors that, in an environment with high interest rates, it would be worse off than banks that did not cater to tech startups and venture capital–backed companies; (3) the Company failed to disclose that, if its investments were negatively affected by rising interest rates, it was particularly susceptible to a bank run; (4) as a result, defendants' public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the SVB class action, go to https://rosenlegal.com/submit–form/?case_id=12882 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8793600)

RVYL, GBOX DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages RYVYL Inc. f/k/a Greenbox POS Investors with Losses in Excess of $100K to Secure Counsel Before Important April 3 Deadline in Securities Class Action Initiated by the Firm – RVYL, GBOX

NEW YORK, March 22, 2023 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ryvyl Inc. f/k/a Greenbox POS (NASDAQ: RVYL, GBOX): (i) pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's January 29, 2021 public offering (the "Offering"); and/or (ii) between January 29, 2021 and January 20, 2023, both dates inclusive (the "Class Period"), of the April 3, 2023 lead plaintiff deadline in the securities class action commenced by the Firm.

SO WHAT: If you purchased Ryvyl securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Ryvyl class action, go to https://rosenlegal.com/submit–form/?case_id=11425 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 3, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, the Registration Statement was false and/or misleading and/or failed to disclose that: (1) the Company would restate certain financials; (2) the Company's internal controls were inadequate; (3) the Company downplayed and obfuscated its internal controls issues; and (4) as a result, the Registration Statement was materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Ryvyl class action, go to https://rosenlegal.com/submit–form/?case_id=11425 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8793573)

ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages PLDT Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action Initiated by the Firm – PHI

NEW YORK, March 22, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of PLDT Inc. (NYSE: PHI) between January 1, 2019 and December 19, 2022, both dates inclusive (the "Class Period"), of the important April 7, 2023 lead plaintiff deadline in the securities class action commenced by the Firm.

SO WHAT: If you purchased PLDT securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the PLDT class action, go to https://rosenlegal.com/submit–form/?case_id=10686 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 7, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose, among other things, that: (1) there were capital spending budget overruns; (2) defendants failed to address weaknesses that allowed such budget overruns; and (3) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the PLDT class action, go to https://rosenlegal.com/submit–form/?case_id=10686 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8793570)